- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Alamar Biosciences launches immune profiling panel for research | 1 | Investing.com | ||
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 28.07. | Alamar Biosciences stellt neues Panel zur Immunprofilierung für die Forschung vor | 2 | Investing.com Deutsch | ||
| 28.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome | 382 | GlobeNewswire (Europe) | Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Highly sensitive... ► Artikel lesen | |
| 27.07. | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | Small- & Micro Cap Investment | |||
| 15.07. | Alamar Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Health Wave Partners Acquires Alamar Senior Living | 1 | pulse2.com | ||
| 14.07. | Alamar Biosciences, Inc.: Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | Alamar Biosciences, Inc.: Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases | 437 | GlobeNewswire (Europe) | National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq Neuro 220 panel.
Resulting... ► Artikel lesen | |
| 10.07. | Alamar's platform to feature in 140+ presentations at AAIC | 1 | Investing.com | ||
| 10.07. | Über 140 Präsentationen: Alamar-Plattform im Fokus der internationalen Alzheimer-Konferenz | 1 | Investing.com Deutsch | ||
| 10.07. | Alamar Biosciences, Inc.: Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling | 597 | GlobeNewswire (Europe) | Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and stagingFREMONT, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences... ► Artikel lesen | |
| 07.07. | Alamar launches blood test for Alzheimer's tau tangles | 4 | Investing.com | ||
| 07.07. | Alamar Biosciences, Inc.: Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research | 508 | GlobeNewswire (Europe) | eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease
Immunoassay... ► Artikel lesen | |
| 09.06. | Stifel reiterates Buy rating on Alamar Biosciences stock at $28 | 1 | Investing.com | ||
| 02.06. | Alamar Biosciences, Inc.: Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics | 531 | GlobeNewswire (Europe) | NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices
Workflow extends NULISA into longitudinal... ► Artikel lesen | |
| 12.05. | TD Cowen initiates Alamar Biosciences stock with buy rating | 12 | Investing.com | ||
| 12.05. | JPMorgan initiates Alamar Biosciences stock with overweight rating | 1 | Investing.com | ||
| 12.05. | Stifel initiates Alamar Biosciences stock with buy rating | 2 | Investing.com | ||
| 08.05. | Alamar Biosciences, Inc. GAAP EPS of -$1.74, revenue of $26M | 1 | Seeking Alpha | ||
| 08.05. | Alamar Biosciences, Inc.: Alamar Biosciences Reports First Quarter 2026 Financial Results | 465 | GlobeNewswire (Europe) | FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 25,940 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 57,98 | -0,10 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| NURIX THERAPEUTICS | 23,220 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093)... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,210 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| CG ONCOLOGY | 69,15 | 0,00 % | CG Oncology stock maintained at Buy by H.C. Wainwright on trial data | ||
| EDGEWISE THERAPEUTICS | 38,380 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| ANNEXON | 5,250 | 0,00 % | Annexon Biosciences: Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance | BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,11 | 0,00 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| RECURSION PHARMACEUTICALS | 3,180 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| VERADERMICS | 101,54 | -0,32 % | Weekly Buzz: Novartis, Merck & Co. Win FDA Nod; Eli Lilly Snaps Up AtaiBeckley; Veradermics Shines On Hair Loss Data | BASEL (dpa-AFX) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,40 | -0,04 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| KYMERA THERAPEUTICS | 100,19 | -0,12 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,235 | -0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 49,260 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| ERASCA | 17,830 | -0,06 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen |
ALAMAR BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 27,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.